Drug Profile

Research programme: antibody therapeutics - Exelixis/Invenra

Alternative Names: Invenra #1; Invenra #2

Latest Information Update: 18 Nov 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Exelixis; Invenra
Class Antibodies; Antineoplastics; Bispecific antibodies; Immunotherapies
Mechanism of Action CD47 antigen inhibitors; Immunomodulators; NK cell lectin-like receptor subfamily C antagonists; Programmed cell death-1 ligand-1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

12 Oct 2022 Preclinical trials in Cancer in USA (Parenteral) (Invenra Pipeline, October 2022)
28 Jun 2022 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral, Injection)
02 May 2018 Exelixis collaborates with Invenra for discovery, development and commercialisation of multispecific antibodies for Cancer

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com